Article Text

PDF

THU0203 Incidence of chloroquine retinopahy in rheumatoid arthritis patients
  1. J Gonzalez-Dominguez1,
  2. M Santos2,
  3. A Escudero1,
  4. A Cisnal1,
  5. M Romero1,
  6. V Perez1,
  7. MD Lopez1,
  8. MA Caracuel1,
  9. FG Martinez1,
  10. JM Gallardo2,
  11. E Collantes1
  1. 1Rheumatology
  2. 2Ophthalmology, Hospital Universitario Reina Sofia, Cordoba, Spain

Abstract

Objectives To evaluate risk of chloroquine (CQ) retinal toxicity in rheumatoid arthritis (RA) patients.

Methods Retrospective case-control study of RA patients attended from 1987 to 1999 in our Rheumatology Service. One hundred and fifty RA patients (120 females (F) and 30 males (M) with a mean age of 64 ± 40 years, who lives in the same geographical area, received daily CQ dosage of 250 mg. Ophthalmologic examination was carried out exam previous CQ treatment and toxicity routine ophthalmic screening every 6 months include fundus, central campimetry and tests of colours Farnsworth D-28. After identification of central visual field alteration and/or fundus CQ treatment was stopped.

Results Eight patients (5.3%), 8 females with mean age of 63.6 ± 11.4 years were identify with CQ retinopathy. Six patients (5F and 1 M) 4% with visual colour defects without CQ retinopathy were detected. Rheumatoid factor (RF) was present in 75% of retinopathy CQ patients (group A) vs. 72.6% in the patients without retinopathy (group B). The duration of treatment and cumulative total dose of CQ was in group A 3.4 ± 2.1 yrs. and 193.7 ± 104.4 gm vs. 3.3 ± 2.6 yrs. and 184 ± 125.9 gm in group B group.

Conclusion The CQ retinal toxicity was of 5.3%, not related with age, rheumatoid factor, duration of treatment and cumulative total dose.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.